Inhaled medicines: past, present, and future
The purpose of this review is to summarize essential pharmacological, pharmaceutical, and
clinical aspects in the field of orally inhaled therapies that may help scientists seeking to …
clinical aspects in the field of orally inhaled therapies that may help scientists seeking to …
Scientific and regulatory activities initiated by the US food and drug administration to foster approvals of generic dry powder inhalers: bioequivalence perspective
Regulatory science for generic dry powder inhalers (DPIs) in the United States (US) has
evolved over the last decade. In 2013, the US Food and Drug Administration (FDA) …
evolved over the last decade. In 2013, the US Food and Drug Administration (FDA) …
Exploring the intrinsic micro−/nanoparticle size on their in vivo fate after lung delivery
Q Liu, X Zhang, J Xue, J Chai, L Qin, J Guan… - Journal of Controlled …, 2022 - Elsevier
Micro−/nanocarriers due to their significant advantages are widely investigated in pulmonary
drug delivery. However, different size carriers have varied drug release rate, concealing the …
drug delivery. However, different size carriers have varied drug release rate, concealing the …
[HTML][HTML] Particulate bioaerogels for respiratory drug delivery
The bioaerogel microparticles have been recently developed for respiratory drug delivery
and attract fast increasing interests. These highly porous microparticles have ultralow …
and attract fast increasing interests. These highly porous microparticles have ultralow …
Optimization of the Transwell® System for Assessing the Dissolution Behavior of Orally Inhaled Drug Products through In Vitro and In Silico Approaches
The aim of this study was to further evaluate and optimize the Transwell® system for
assessing the dissolution behavior of orally inhaled drug products (OIDPs), using fluticasone …
assessing the dissolution behavior of orally inhaled drug products (OIDPs), using fluticasone …
[图书][B] Advancing Bioequivalence Assessments of Orally Inhaled and Nasal Drug Products (OINDPs) Through In Vitro, In Vivo, and In Silico Approaches
E Amini - 2022 - search.proquest.com
For bioequivalence (BE) assessment of orally inhaled and nasal drug products (OINDPs),
the US FDA still recommends a weight-of-evidence approach which, in addition to …
the US FDA still recommends a weight-of-evidence approach which, in addition to …
Inhalation Biopharmaceutics
P Akhuemokhan, M Swedrowska… - … : From Fundamentals to …, 2022 - Wiley Online Library
Factors affecting deposition may be patient‐specific such as inspiratory profile, lung luminal
conditions, and airway geometry or drug product dependent such as inhalation device or …
conditions, and airway geometry or drug product dependent such as inhalation device or …
[引用][C] Considerations and Challenges for Dissolution Testing of Orally Inhaled Drug Products (OIDPs)
ER Bielski - 2023